Ascentage Pharma Group International furnishes SEC filings as a foreign private issuer reporting under Form 6-K and indicating annual reporting on Form 20-F. The filings document press releases and Hong Kong Stock Exchange announcements for annual results, oncology pipeline updates, clinical and preclinical presentation materials, and changes in corporate administration.
The company’s filing record also includes Hong Kong annual report and environmental, social and governance materials, annual general meeting notices, proxy forms, director re-election matters, general mandates to issue or repurchase shares, and supplemental equity-incentive grant proposals under its RSU and post-IPO share option schemes.
Ascentage Pharma Group International (AAPG) announced that the Trustee purchased 200,000 existing shares on-market on October 27, 2026 for the 2022 RSU Scheme, to satisfy RSUs upon vesting. Total consideration was HK$5,644,472, excluding related expenses, transaction levy, brokerage, tax, duties and levies; average consideration was approximately HK$28.22 per share.
The purchased shares represented approximately 0.05% of issued shares as of the announcement date. Immediately after the purchase, the Trustee held 3,315,000 existing shares purchased on-market for the scheme. The Trustee will not exercise voting rights attached to shares it holds on trust.
Ascentage Pharma Group International said the trustee purchased 200,000 existing shares on-market on October 22, 2026, for the 2022 RSU Scheme to satisfy RSUs upon vesting. Total consideration was HK$5,740,622, excluding related expenses, transaction levy, brokerage, tax, duties and levies; average consideration was approximately HK$28.70 per share. The trustee’s total on-market purchases for the scheme stood at 3,115,000 shares immediately after this purchase.
Ascentage Pharma Group International (AAPG) announced that lisaftoclax (APG-2575), combined with acalabrutinib, received Breakthrough Therapy Designation in China for treatment-naïve adults with CLL/SLL. The designation provides priority for communications and development guidance from the Center for Drug Evaluation. If the applicant meets relevant conditions after evaluation, it may apply for Priority Review and conditional approval with a New Drug Application in China.
Lisaftoclax was approved in China in July 2025 for adults with CLL/SLL who had received at least one systemic therapy including a BTK inhibitor. The combination is investigational and has not been approved in any market. Ascentage Pharma is conducting four global registrational Phase III trials; GLORA-2 evaluates the combination as a first-line treatment.
Ascentage Pharma Group International’s trustee purchased 200,000 existing shares on-market on October 15, 2026, for the 2022 RSU Scheme to satisfy RSUs upon vesting. The total consideration was HK$5,778,916, and the average consideration was approximately HK$28.89 per share; both figures exclude all related expenses, transaction levy, brokerage, tax, duties and levies. The purchase represented approximately 0.05% of issued shares as of October 15, 2026. Immediately after the purchase, the trustee had purchased a total of 2,915,000 existing shares on-market for the scheme. The trustee shall not exercise voting rights attached to shares held on trust.
Ascentage Pharma Group International (AAPG) reported that the trustee for its 2022 RSU Scheme purchased 50,000 existing shares on-market on September 28, 2026, for HK$1,428,000, excluding related expenses, taxes and other charges. The average consideration was approximately HK$28.56 per share. The shares are held to satisfy RSUs upon vesting, and the trustee does not exercise their voting rights. Immediately after the purchase, the trustee had purchased 2,715,000 existing shares on-market for the scheme.
The company also reported that Chairman and Executive Director Dr. Dajun Yang acquired 38,630 shares on-market on September 23, September 24 and September 25, 2026, for total consideration of approximately HK$1,157,137 and an average price of approximately HK$29.95 per share. Afterward, he was deemed interested in 62,570,254 shares, representing approximately 16.69% of issued share capital. The company said Dr. Yang advised that the acquisitions indicate his confidence in its prospects.
ASCENTAGE PHARMA GROUP INTERNATIONAL (AAPG) reports higher revenue but significantly wider losses for the six months ended June 30, 2026. Revenue rose to RMB302.2 million from RMB233.7 million, driven by commercialization of Olverembatinib and the first full periods of Lisaftoclax sales and related commercialization income.
The company remains highly R&D-intensive, with research and development expenses increasing to RMB697.5 million, alongside selling and distribution expenses of RMB226.4 million as it builds out its commercial footprint in China. This contributed to a larger loss of RMB817.0 million and net operating cash outflow of RMB581.2 million. Cash and bank balances were RMB1,895.6 million, while interest-bearing borrowings reached RMB2,094.6 million and the gearing ratio was 35.8%, with the current ratio at 1.2.
Strategically, Ascentage highlights a global oncology pipeline anchored by approved products Olverembatinib and Lisaftoclax, multiple Phase III registrational trials, extensive Orphan Drug and pediatric designations, and an exclusive option agreement under which Takeda may license Olverembatinib ex‑Greater China and Russia. The group also emphasizes expansion of its Suzhou manufacturing center, NRDL coverage for Olverembatinib, and guideline endorsements that support the long-term commercialization outlook.
Ascentage Pharma Group International (AAPG) reported strong top-line growth but widening losses for the six months ended June 30, 2026. Revenue rose to RMB302.2 million (US$44.5 million) from RMB233.7 million a year earlier, driven mainly by product sales, which increased 32.6% to RMB282.4 million (US$41.6 million). The commercial ramp of Olverembatinib and Lisaftoclax in China underpins this growth, supported by broader hospital coverage and NRDL inclusion for Olverembatinib.
Operating investment accelerated. Research and development expenses increased 32.0% to RMB697.5 million (US$102.8 million), and selling and distribution expenses rose 64.3% to RMB226.4 million (US$33.4 million), mainly for Lisaftoclax promotion. As a result, net loss widened to RMB817.0 million (US$120.4 million), with basic and diluted loss per share of RMB2.19 (US$0.32). Cash and bank balances declined to RMB1,895.6 million (US$279.4 million) from RMB2,470.1 million at year-end 2025, reflecting operating cash outflows of RMB581.2 million despite new bank borrowings. The company continues to advance a broad oncology pipeline, including multiple global Phase III trials for Olverembatinib and Lisaftoclax and early programs such as BTK degrader APG-3288.
Ascentage Pharma Group International reports that it will release its unaudited six‑month 2026 interim results and provide business updates at 7:00 am EDT / 7:00 pm HKT on August 19, 2026, followed by investor webcasts in Mandarin and English. A Mandarin webcast is scheduled for 9:00 pm EDT on August 19, 2026 / 9:00 am HKT on August 20, 2026, and an English conference call and webcast for 8:00 am EDT / 8:00 pm HKT on August 20, 2026.
The company also states that management will participate in the Evercore ISI 2nd Annual China Biotech Summit, held August 17‑19, 2026 in Shanghai, including a fireside chat on August 18, 2026 from 7:45 to 8:00 am Beijing time and one‑on‑one investor meetings. The disclosure reiterates that Ascentage Pharma is a commercial‑stage oncology‑focused biopharmaceutical company with two approved products, Olverembatinib and Lisaftoclax, and multiple FDA‑ and EMA‑cleared registrational Phase III trials.
Ascentage Pharma Group International filed a Form 6-K as a foreign private issuer, furnishing a Hong Kong announcement that its Board will hold a meeting on Wednesday, August 19, 2026. The Board will consider, among other matters, approving the Group’s unaudited interim results for the six months ended June 30, 2026 and their publication.
The announcement also lists the current Board composition, including an executive Chairman, non-executive Directors and several independent non-executive Directors, reflecting the company’s governance structure.
Ascentage Pharma Group International appointed Dr. Faiçal Miyara as Chief Business Officer and Jim Ziegler as Chief Commercial Officer. Dr. Miyara will lead global business development, while Mr. Ziegler will oversee commercialization of products in the United States and other markets outside China; both report to Chairman and CEO Dr. Dajun Yang.
The company describes itself as a global, commercial-stage biopharmaceutical group focused on novel cancer therapies, including the approved products olverembatinib and lisaftoclax and multiple FDA- and EMA-cleared registrational Phase III trials in chronic myeloid leukemia, Ph+ ALL, SDH-deficient GIST, CLL/SLL, AML and higher-risk MDS.